AbbVie’s new AI deal; Roche's PhIII win in breast cancer; SpringWorks to raise $275M
05 Dec 2023
Clinical ResultIPO
Plus, news about Eligo Bioscience, EyePoint, Xenon and Merus:
AbbVie signs AI pact:
For $30 million upfront, the pharma is
partnering
with
BigHat Biosciences
to develop new antibodies in oncology and neuroscience. It’s the second biopharma
AI alliance to be announced on Tuesday
. AbbVie could dish out up to $325 million more in R&D milestones.
— Kyle LaHucik
Roche touts PhIII breast cancer win for PI3K alpha drug:
The Big Pharma’s inavolisib plus Pfizer’s Ibrance achieved a statistically significant
improvement
in the primary endpoint of progression-free survival in people with PIK3CA-mutated HR-positive HER2-negative advanced or metastatic disease. Roche plans to present the full data at a future meeting and then submit them to health authorities.
— Ayisha Sharma
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.